Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil

Xu Wang, Monica X. Li, Brian D. Sykes

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Cardiac troponin C (cTnC) is the Ca2+-dependent switch for contraction in heart muscle and a potential target for drugs in the therapy of heart failure. Ca2+ binding to the regulatory domain of cTnC (cNTnC) induces little structural change but sets the stage for cTnI binding. A large "closed" to "open" conformational transition occurs in the regulatory domain upon binding ctnI147-163 or bepridil. This raises the question of whether cTnI147-163 and bepridil compete for cNTnC·Ca2+. In this work, we used two-dimensional 1H,15N-heteronuclear single quantum coherence (HSQC) NMR spectroscopy to examine the binding of bepridil to cNTnC·Ca2+ in the absence and presence of cTnI147-163 and of ctnI147-163 to cNTnC·Ca2+ in the absence and presence of bepridil. The results show that bepridil and ctnI147-163 bind cNTnC·Ca2+ simultaneously but with negative cooperativity. The affinity of cTnI147-163 for cNTnC·Ca2+ is reduced ∼3.5-fold by bepridil and vice versa. Using multinuclear and multidimensional NMR spectroscopy, we have determined the structure of the cNTnC· Ca2+·cTnI147-163·bepridil ternary complex. The structure reveals a binding site for cTnI147-163 primarily located on the A/B interhelical interface and a binding site for bepridil in the hydrophobic pocket of cNTnC·Ca2+. In the structure, the N terminus of the peptide clashes with part of the bepridil molecule, which explains the negative cooperativity between cTnI147-163 and bepridil for cNTnC·Ca2+. This structure provides insights into the features that are important for the design of cTnC-specific cardiotonic drugs, which may be used to modulate the Ca2+ sensitivity of the myofilaments in heart muscle contraction.

Original languageEnglish (US)
Pages (from-to)31124-31133
Number of pages10
JournalJournal of Biological Chemistry
Volume277
Issue number34
DOIs
StatePublished - Aug 23 2002
Externally publishedYes

Fingerprint

Bepridil
Troponin C
Troponin
Nuclear magnetic resonance spectroscopy
Muscle
Myocardium
Magnetic Resonance Spectroscopy
Binding Sites
Biomolecular Nuclear Magnetic Resonance
Cardiotonic Agents
Myofibrils
Muscle Contraction
Heart Failure
Switches

ASJC Scopus subject areas

  • Biochemistry

Cite this

Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil. / Wang, Xu; Li, Monica X.; Sykes, Brian D.

In: Journal of Biological Chemistry, Vol. 277, No. 34, 23.08.2002, p. 31124-31133.

Research output: Contribution to journalArticle

@article{d734800c1d3a43059a298a89dd8be822,
title = "Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil",
abstract = "Cardiac troponin C (cTnC) is the Ca2+-dependent switch for contraction in heart muscle and a potential target for drugs in the therapy of heart failure. Ca2+ binding to the regulatory domain of cTnC (cNTnC) induces little structural change but sets the stage for cTnI binding. A large {"}closed{"} to {"}open{"} conformational transition occurs in the regulatory domain upon binding ctnI147-163 or bepridil. This raises the question of whether cTnI147-163 and bepridil compete for cNTnC·Ca2+. In this work, we used two-dimensional 1H,15N-heteronuclear single quantum coherence (HSQC) NMR spectroscopy to examine the binding of bepridil to cNTnC·Ca2+ in the absence and presence of cTnI147-163 and of ctnI147-163 to cNTnC·Ca2+ in the absence and presence of bepridil. The results show that bepridil and ctnI147-163 bind cNTnC·Ca2+ simultaneously but with negative cooperativity. The affinity of cTnI147-163 for cNTnC·Ca2+ is reduced ∼3.5-fold by bepridil and vice versa. Using multinuclear and multidimensional NMR spectroscopy, we have determined the structure of the cNTnC· Ca2+·cTnI147-163·bepridil ternary complex. The structure reveals a binding site for cTnI147-163 primarily located on the A/B interhelical interface and a binding site for bepridil in the hydrophobic pocket of cNTnC·Ca2+. In the structure, the N terminus of the peptide clashes with part of the bepridil molecule, which explains the negative cooperativity between cTnI147-163 and bepridil for cNTnC·Ca2+. This structure provides insights into the features that are important for the design of cTnC-specific cardiotonic drugs, which may be used to modulate the Ca2+ sensitivity of the myofilaments in heart muscle contraction.",
author = "Xu Wang and Li, {Monica X.} and Sykes, {Brian D.}",
year = "2002",
month = "8",
day = "23",
doi = "10.1074/jbc.M203896200",
language = "English (US)",
volume = "277",
pages = "31124--31133",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "34",

}

TY - JOUR

T1 - Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil

AU - Wang, Xu

AU - Li, Monica X.

AU - Sykes, Brian D.

PY - 2002/8/23

Y1 - 2002/8/23

N2 - Cardiac troponin C (cTnC) is the Ca2+-dependent switch for contraction in heart muscle and a potential target for drugs in the therapy of heart failure. Ca2+ binding to the regulatory domain of cTnC (cNTnC) induces little structural change but sets the stage for cTnI binding. A large "closed" to "open" conformational transition occurs in the regulatory domain upon binding ctnI147-163 or bepridil. This raises the question of whether cTnI147-163 and bepridil compete for cNTnC·Ca2+. In this work, we used two-dimensional 1H,15N-heteronuclear single quantum coherence (HSQC) NMR spectroscopy to examine the binding of bepridil to cNTnC·Ca2+ in the absence and presence of cTnI147-163 and of ctnI147-163 to cNTnC·Ca2+ in the absence and presence of bepridil. The results show that bepridil and ctnI147-163 bind cNTnC·Ca2+ simultaneously but with negative cooperativity. The affinity of cTnI147-163 for cNTnC·Ca2+ is reduced ∼3.5-fold by bepridil and vice versa. Using multinuclear and multidimensional NMR spectroscopy, we have determined the structure of the cNTnC· Ca2+·cTnI147-163·bepridil ternary complex. The structure reveals a binding site for cTnI147-163 primarily located on the A/B interhelical interface and a binding site for bepridil in the hydrophobic pocket of cNTnC·Ca2+. In the structure, the N terminus of the peptide clashes with part of the bepridil molecule, which explains the negative cooperativity between cTnI147-163 and bepridil for cNTnC·Ca2+. This structure provides insights into the features that are important for the design of cTnC-specific cardiotonic drugs, which may be used to modulate the Ca2+ sensitivity of the myofilaments in heart muscle contraction.

AB - Cardiac troponin C (cTnC) is the Ca2+-dependent switch for contraction in heart muscle and a potential target for drugs in the therapy of heart failure. Ca2+ binding to the regulatory domain of cTnC (cNTnC) induces little structural change but sets the stage for cTnI binding. A large "closed" to "open" conformational transition occurs in the regulatory domain upon binding ctnI147-163 or bepridil. This raises the question of whether cTnI147-163 and bepridil compete for cNTnC·Ca2+. In this work, we used two-dimensional 1H,15N-heteronuclear single quantum coherence (HSQC) NMR spectroscopy to examine the binding of bepridil to cNTnC·Ca2+ in the absence and presence of cTnI147-163 and of ctnI147-163 to cNTnC·Ca2+ in the absence and presence of bepridil. The results show that bepridil and ctnI147-163 bind cNTnC·Ca2+ simultaneously but with negative cooperativity. The affinity of cTnI147-163 for cNTnC·Ca2+ is reduced ∼3.5-fold by bepridil and vice versa. Using multinuclear and multidimensional NMR spectroscopy, we have determined the structure of the cNTnC· Ca2+·cTnI147-163·bepridil ternary complex. The structure reveals a binding site for cTnI147-163 primarily located on the A/B interhelical interface and a binding site for bepridil in the hydrophobic pocket of cNTnC·Ca2+. In the structure, the N terminus of the peptide clashes with part of the bepridil molecule, which explains the negative cooperativity between cTnI147-163 and bepridil for cNTnC·Ca2+. This structure provides insights into the features that are important for the design of cTnC-specific cardiotonic drugs, which may be used to modulate the Ca2+ sensitivity of the myofilaments in heart muscle contraction.

UR - http://www.scopus.com/inward/record.url?scp=0037163141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037163141&partnerID=8YFLogxK

U2 - 10.1074/jbc.M203896200

DO - 10.1074/jbc.M203896200

M3 - Article

VL - 277

SP - 31124

EP - 31133

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 34

ER -